Project leads
Collaborators

A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT

Joseph H Antin

0 Collaborator(s)

Funding source

National Institutes of Health (NIH)

Follow

Joseph H Antin

Dana-Farber Cancer Institute

Boston, United States

Related projects

Peng Huang

Novel Strategies to Target Leukemia-Stromal Interactions

Laura Pasqualucci

Role of MLL2 Gene Inactivation in B cell Non Hodgkin Lymphoma

Non-Hodgkin lymphoma

Hematology and hematologic malignancies Pathology

Oliver W Press

Pretargeted Radioimmunotherapy of CD20+ Lymphomas

Non-Hodgkin lymphoma

Hematology and hematologic malignancies Radiation Oncology Pathology

Marina Y Konopleva

Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia

Ulrich G. Steidl

Role of a Novel Homeobox Transcription Factor (HLX) in Acute Myeloid Leukemia

Kevin A Goncalves

Role of Angiogenin in Hematopoietic Stem Cell Quiescence and Self-renewal

Alan B. Cantor

Regulation of RUNX1 Multiprotein Complex Formation during Hematopoiesis

Hematology and hematologic malignancies

Paul M Thompson

ENIGMA Center for Worldwide Medicine, Imaging & Genomics

Alan Rein

Retrovirus Assembly and Maturation

Hematology and hematologic malignancies Pathology